Cargando…
Outcomes of Secondary Hyperparathyroidism in Chronic Kidney Disease and the Direct Costs of Treatment
BACKGROUND: There has been an emphasis over the last several years to identify and treat chronic kidney disease (CKD) and its complications as they evolve rather than waiting until the patient reaches end-stage renal disease (ESRD), also known as CKD stage 5. The number of patients who will be ident...
Autores principales: | Joy, Melanie S., Karagiannis, Paul C., Peyerl, Fred W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437388/ https://www.ncbi.nlm.nih.gov/pubmed/17605511 http://dx.doi.org/10.18553/jmcp.2007.13.5.397 |
Ejemplares similares
-
Cost-effectiveness analysis of cinacalcet vs. paricalcitol in the
treatment of hyperparathyroidism secondary to chronic kidney
disease
por: Ponce, Daniela, et al.
Publicado: (2023) -
Oral Paricalcitol for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease
por: Cheng, Steven, et al.
Publicado: (2006) -
Secondary hyperparathyroidism and adverse health outcomes in adults with chronic kidney disease
por: Xu, Yang, et al.
Publicado: (2021) -
Secondary hyperparathyroidism among Nigerians with chronic kidney disease
por: Gimba, Zumnan M, et al.
Publicado: (2018) -
Secondary Hyperparathyroidism in Chronic Kidney Disease: Pathophysiology and Management
por: Habas, Elmukhtar, et al.
Publicado: (2021)